Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Overall Survival
79%
Durvalumab
72%
Small Cell Lung Cancer
72%
Abdominal Cancer
60%
Etoposide
51%
Progression Free Survival
50%
Diseases
39%
Cisplatin
36%
Gemcitabine
36%
Adverse Event
33%
Neoplasm
30%
Malignant Neoplasm
30%
Phase III Trials
30%
Pancreas Cancer
29%
Tremelimumab
28%
Epidermal Growth Factor Receptor
27%
First-Line Chemotherapy
27%
Protein Tyrosine Kinase Inhibitor
25%
Adenoid Cystic Carcinoma
24%
Randomized Controlled Trial
24%
Biliary Tract Cancer
24%
Docetaxel
24%
Brain Metastasis
24%
Chemoradiation Therapy
24%
Capecitabine Plus Oxaliplatin
24%
Survival Rate
24%
Biological Marker
23%
Oxaliplatin
21%
Epidermal Growth Factor Receptor Kinase Inhibitor
19%
Disease Exacerbation
18%
Colorectal Carcinoma
17%
Non Small Cell Lung Cancer
17%
Bile Duct Carcinoma
16%
Phase II Trials
16%
Adenocarcinoma
15%
Lung Cancer
15%
Skin Toxicity
14%
Monotherapy
13%
Marginal Zone Lymphoma
12%
Second-Line Chemotherapy
12%
Cetuximab
12%
Methylprednisolone
12%
Dexamethasone
12%
Pancreas Adenocarcinoma
12%
Paclitaxel
12%
Vismodegib
12%
Rituximab
12%
Observational Study
12%
Stomach Tumor
12%
Medicine and Dentistry
Overall Survival
66%
Durvalumab
60%
Small Cell Lung Cancer
60%
Biliary Tract Cancer
48%
Progression Free Survival
42%
Cholangiocarcinoma
41%
Hazard Ratio
37%
Adjuvant Therapy
36%
Diseases
35%
Malignant Neoplasm
32%
Neoplasm
31%
Etoposide
28%
Ticilimumab
28%
Supportive Care
24%
Gemcitabine
24%
Cylindroma
24%
Abdominal Cancer
24%
Biological Marker
23%
Cisplatin
20%
Phase II Trials
18%
Propensity Score Matching
18%
Brain Metastasis
16%
Disease Exacerbation
16%
Axitinib
15%
Metastatic Carcinoma
14%
Radiation Therapy
14%
Gallbladder Cancer
14%
Targeted Therapy
13%
Lymph Node
13%
Recurrence Free Survival
13%
Carcinoembryonic Antigen
13%
Arm
13%
Chemoradiotherapy
12%
Thyroid Carcinoma
12%
Bile Duct Cancer
12%
Terminal Illness
12%
Follicular Lymphoma International Prognostic Index
12%
Colorectal Carcinoma
12%
Cetuximab
12%
Capecitabine Plus Oxaliplatin
12%
CHOP
12%
Maintenance Therapy
12%
Tumor Infiltrating Lymphocyte
12%
Sunitinib
12%
Buprenorphine
12%
Transdermal
12%
First-Line Chemotherapy
12%
Whole Brain Radiotherapy
12%
Diffuse Large B-Cell Lymphoma
12%
Trastuzumab
12%
Biochemistry, Genetics and Molecular Biology
Genomics
24%
Immune Checkpoints
24%
Isoform
24%
Overall Survival
22%
Vismodegib
12%
Hormone Receptor
12%
CA 15-3
12%
Immunocompetent Cell
12%
Anaplastic Lymphoma Kinase
12%
Fusion Gene
12%
Epidermal Growth Factor Receptor
12%
Phosphoinositide 3-Kinase
12%
Sunitinib
12%
Next Generation Sequencing
12%
Circulating Tumor DNA
12%
Hsp90
12%
Heat Shock Protein
12%
Carcinogenesis
9%
Estrogen Receptor
8%
Clinical Trial
7%
Multivariate Analysis
7%
Progesterone Receptor
6%
Mucin
6%
Exon
6%
Drug Therapy
6%
MEK Inhibitor
6%
Protein Kinase B
6%
Somatic Mutation
6%
TSC2
6%
Genetic Trait
6%
Cisplatin
6%
Tissue Microarray
5%
Recurrence Free Survival
5%